With anti-CD38 in multiple myeloma, a survival benefit too long to be significant?

被引：0
|
作者：
Cazabat, Romain
机构：
来源：
HEMATOLOGIE | 2024年 / 30卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：10
相关论文
共 50 条
  • [31] ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER
    Pimentel, Villar M. A.
    Anguita, Arance M. M.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2021, 106 (10) : 337 - 337
  • [32] Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Tan, Carlyn Rose Co
    Rueda, Colin
    Shekarkhand, Tala
    Derkach, Andriy
    Korde, Neha
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Usmani, Saad Zafar
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] CLINICAL OUTCOMES ASSOCIATED WITH ANTI-CD38 RETREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REVIEW OF THE LITERATURE
    McNamara, S.
    Chorazy, J.
    Pandey, A.
    Bitetti, J.
    Boytsov, N.
    Purser, M.
    Iheanacho, I.
    VALUE IN HEALTH, 2024, 27 (06) : S31 - S31
  • [34] Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
    Tan, Chia Jie
    Kacerek, Dylan
    Kampirapawong, Nattawara
    Godara, Amandeep
    Chaiyakunapruk, Nathorn
    CANCER MEDICINE, 2025, 14 (05):
  • [35] Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication
    Tai, Yu-Tzu
    de Weers, Michel
    Li, Xian-Feng
    Song, Weihua
    Nahar, Sabikun
    Bakker, Joost M.
    Vink, Tom
    Jacobs, Danielle
    Oomen, Lukas
    Bleeker, Wim K.
    Munshi, Nikhil C.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    Richardson, Paul
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 252 - 252
  • [36] Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma
    Ziccheddu, Bachisio
    Giannotta, Claudia
    D'Agostino, Mattia
    Bertuglia, Giuseppe
    Saraci, Elona
    Oliva, Stefania
    Diamond, Benjamin
    Bolli, Niccolo
    Corradini, Paolo
    Coffey, David
    Landgren, Ola
    Bruno, Benedetto
    Boccadoro, Mario
    Massaia, Massimo
    Maura, Francesco
    Larocca, Alessandra
    BLOOD, 2023, 142
  • [37] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Oses, Lucrecia
    Brulc, Erika
    Carretero, Marcelina
    Nucifora, Elsa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [38] Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
    Caroni, Federico
    Sammartano, Vincenzo
    Pacelli, Paola
    Sicuranza, Anna
    Malchiodi, Margherita
    Dragomir, Andreea
    Ciofini, Sara
    Raspadori, Donatella
    Bocchia, Monica
    Gozzetti, Alessandro
    PHARMACEUTICALS, 2025, 18 (02)
  • [39] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Aleman, Adolfo
    Zajdman, Ariel Kogan
    Mouhieddine, Tarek
    Upadhyaya, Bhaskar
    Van Oekelen, Oliver
    Lagana, Alessandro
    Grossman, Leah
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Richter, Joshua
    Cho, Hearn Jay
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
  • [40] COST OF ANTI-CD38 MONOCLONAL ANTIBODIES IN COMBINATION WITH CARFILZOMIB AND DEXAMETHASONE FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
    Lin, P.
    Petitjean, A.
    Drea, E.
    Lin, F.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
12345